Navigation Links
iCo Therapeutics Announces Second Quarter 2014 Financial Results
Date:8/29/2014

nsive loss of $1,617,040 (loss per share of $0.02) for the six months ended June 30, 2014 compared to a total comprehensive loss of $2,886,831 (loss per share of $0.05) for the six months ended June 30, 2013, representing a decrease of $1,269,791 in comprehensive loss.  The decrease in net comprehensive loss is primarily a result of a $259,755 increase in the carrying value of our investment in Immune Pharmaceuticals, as well as a decrease in expenses associated with the iDEAL trial.

Research and development expenses were $1,026,287 for the six months ended June 30, 2014 compared to $2,189,830 for the six months ended June 30, 2013, representing a reduction of $1,163,543. This decrease in research and development expenses is based mainly on reduced expenses associated with the iDEAL study.

For the six months ended June 30, 2014 general and administrative expenses were $935,374 compared to $1,166,480 for the six months ending June 30, 2013, representing a decrease of $231,106, primarily as a result of reduced stock based compensation expense and professional fees.

Liquidity and Outstanding Share Capital
As at June 30, 2014, we had cash and cash equivalents and short-term investments of $6,480,200. 

As at August 29, 2014, we had an unlimited number of authorized common shares with 84,457,713 common shares issued and outstanding.

For complete financial results, please see our filings at www.sedar.com.

About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The Company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of kerato
'/>"/>

SOURCE iCo Therapeutics Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Chinese Microcrystalline Cellulose Industry Report 2014" report ... Chinese Microcrystalline Cellulose Industry Report 2014 is a professional ... global microcrystalline cellulose industry with a focus on the ... overview of the industry including definitions, classifications, applications and ...
(Date:9/22/2014)... TORONTO , Sept. 22, 2014 /PRNewswire/ ... today announced that it has entered into a ... which UHN,s Centre for Molecular Design and Preformulations ... project.  The goal of the project is to ... Company,s proprietary buccal insulin spray product, thereby reducing ...
(Date:9/22/2014)... Washington, D.C (PRWEB) September 22, 2014 ... the top privately held biotechnology companies of 2014. ... of companies before selecting this year’s winners. Those ... private biotechnology companies in the industry. , ... a new group of Fierce 15 companies," said Carroll. ...
(Date:9/22/2014)... , September 22, 2014 ... on a mixed note as the Dow Jones Industrial ... Composite closed at 4,579.79, down 0.30%. The S&P 500 ... trading session, six out of ten sectors finished on ... Index ended the day at 751.48, up 0.10%, with ...
Breaking Biology Technology:Global and Chinese Microcrystalline Cellulose Industry Report 2014 2Generex Collaborates with University Health Network for Buccal Insulin Project 2Generex Collaborates with University Health Network for Buccal Insulin Project 3Generex Collaborates with University Health Network for Buccal Insulin Project 4FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5
... PRINCETON, N.J., May 1 Ranbaxy Pharmaceuticals ... voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, ... U.S. Although certain lots of the product were ... laboratory specifications, Ranbaxy decided to recall all the lots, ...
... May 1 /PRNewswire-Asia/ -- Yongye Biotechnology International, Inc. (OTC ... distributor of plant and animal nutrient products located in ... of the independently owned Yongye branded retail stores in ... day sales.A Yongye branded retail store in Qianjiang City ...
... 1 Tigris Pharmaceuticals, Inc., a privately held drug ... a Phase I clinical trial of GGTI-2418. GGTI-2418 ... I) that induces apoptosis by downregulating several pivotal oncogenic ... by Dr. Peter O,Dwyer, Professor of Medicine at the ...
Cached Biology Technology:Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 2Yongye Biotechnology Distributor has Record Breaking Single Store Sales Day 3First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 2First Patient Dosed in Phase I Clinical Trial of Tigris Pharmaceuticals' GGTI-2418 3
(Date:9/19/2014)... will study multifunctional and specialized spinal cord nerve ... Science Foundation grant in the amount of $680,000 ... in the Department of Biology, OU College of ... between the multifunctional and specialized spinal cord nerve ... what connections they make. Berkowitz will collaborate ...
(Date:9/19/2014)... Inc. (Nasdaq: NXTD and NXTDW) ("Nxt-ID" or the ... updates the "Wocket in Your Pocket" celebrity ad campaign, featuring former ... classes, Vinny Pazienza (PAZ). , ... actor Ciaran Hinds and Sons of Anarchy ... have been cast in Bleed for This . ...
(Date:9/18/2014)... A new GSA Bulletin study uses ... Rio Puerco and Chaco Wash in northern New Mexico, ... salt cedar and willow, investigators were able to precisely ... They then combined this data with aerial imagery, LiDAR, ... of these arroyos. , Arroyos are deep, oversized channels ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7
... and biological aspects of cellular self-organization are well-studied; less ... how their behavior and communication are affected by ... the University of California San Diego, in a paper ... of the National Academy of Sciences, have begun ...
... Japanese researchers were awarded the 2008 SNM Wagner-Torizuka ... States through 2010 as part of the two-year ... Medical College, undertaking a fellowship at Johns Hopkins ... the University of Washington, Seattle; Ryo Nakazato, Toho ...
... has clearly illustrated, the top priority for the next ... Believing that expanding the nation,s commitment to basic ... the next President can take to ensure our long-term ... questions (attached) to the moderator of tomorrow,s presidential debate. ...
Cached Biology News:UC San Diego bioengineers fill holes in science of cellular self-organization 22008 SNM Wagner-Torizuka Fellowships announced 22008 SNM Wagner-Torizuka Fellowships announced 3The Science Coalition's '10 questions' for the presidential debate 2
... of 3 siRNAs specifically targeted to your ... product. The siTrio reagent guarantees you get ... gene when used under standard conditions (100 ... optimal transfection with one of B-Bridges controls). ...
... a cocktail of 3 siRNAs specifically targeted ... most popular product. The siTrio reagent guarantees ... your target gene when used under standard ... confirmation of optimal transfection with one of ...
... has improved stability and convenience from the former ... has overcome this problem but also produced some ... the formulation of HRP conjugated antibody from lyophilized ... change, the stability of the conjugate has improved ...
... suitable for a wide range of molecular ... Pulsed Field Gel Electrophoresis (PFGE). Due to ... Multi ABgarose can effectively separate large DNA ... turn means reduced band diffusion, a problem ...
Biology Products: